Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

AbstractPurpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insuf...

Full description

Bibliographic Details
Main Authors: Diego Orsini, Giacomo Caldarola, Annunziata Dattola, Elena Campione, Nicoletta Bernardini, Pasquale Frascione, Clara De Simone, Antonio G. Richetta, Marco Galluzzo, Nevena Skroza, Chiara Assorgi, Emanuele Amore, Gennaro M. Falco, Ruslana Gaeta Shumak, Fabio Artosi, Giulia Maretti, Concetta Potenza, Luca Bianchi, Giovanni Pellacani, Ketty Peris, Claudio Bonifati, Dario Graceffa
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Tildrakizumab
immunomodulatory therapies
biologics
psoriasis
psoriasis treatment
anti-IL-23-biologics
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2319304

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2024.2319304

Similar Items